CAPEOX

DRUG17 trials

Conditions

Adjuvant ChemotherapyAnlotinibApatinibChemotherapy EffectColon AdenocarcinomaColon CancerColonic NeoplasmsColorectal Adenoma

Phase 1

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

CompletedNCT00387387

GlaxoSmithKlineNeoplasms, Colorectal

Start: 2006-10-20End: 2009-08-14Updated: 2017-11-17

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruitingNCT05394740

National Cancer Center Hospital EastEsophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2022-06-06End: 2025-11-30Updated: 2024-07-08

Phase 2

Window of Opportunity Study in Colorectal Cancer

CompletedNCT03984578

National Cancer Centre, SingaporeColorectal Cancer

Start: 2019-06-12End: 2025-02-28Updated: 2025-11-18

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

WithdrawnNCT04620473

Shanghai Minimally Invasive Surgery CenterAnlotinib, Neoadjuvant Treatment, Rectal Cancer

Start: 2023-11-01End: 2024-10-01Updated: 2021-09-28

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

NCT05068206

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unresectable Metastatic Colorectal Cancer

Start: 2021-10-08End: 2024-06-30Target: 120Updated: 2021-10-20

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

CompletedNCT05515796

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityChemotherapy Effect, Gastric Cancer, Immunotherapy +2

Start: 2022-09-01End: 2026-03-25Updated: 2026-04-01

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

RecruitingNCT05576480

Ruijin HospitalLocally Advanced, Rectal Cancer

Start: 2023-02-06End: 2026-12-31Target: 55Updated: 2025-08-28

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

NCT05833672

fan liColon Cancer, Immunotherapy

Start: 2023-05-01End: 2025-12-31Target: 100Updated: 2023-04-27

Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

RecruitingNCT06014372

Sun Yat-sen UniversityColon Cancer, Immunotherapy, Neoadjuvant Therapy

Start: 2023-07-01End: 2026-07-01Target: 55Updated: 2024-04-12

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

Not yet recruitingNCT06443671

Peking University Cancer Hospital & InstituteRectal Cancer

Start: 2024-06-01End: 2028-06-01Target: 132Updated: 2024-06-05

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

RecruitingNCT06516445

Huazhong University of Science and TechnologyColorectal Cancer

Start: 2023-06-28End: 2026-06-28Target: 33Updated: 2024-07-24

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

RecruitingNCT06567782

GlaxoSmithKlineNeoplasms, Colon

Start: 2025-02-17End: 2028-10-26Target: 120Updated: 2026-04-02

HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer

RecruitingNCT06709885

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityColon Adenocarcinoma

Start: 2024-10-15End: 2027-09-30Target: 100Updated: 2024-11-29

Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Not yet recruitingNCT06722950

Shandong New Time Pharmaceutical Co., LTDColorectal Adenoma

Start: 2024-12-31End: 2026-12-31Target: 120Updated: 2024-12-09

Phase 3

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

RecruitingNCT05201430

Fudan UniversityRectal Cancer

Start: 2021-08-27End: 2027-07-31Target: 300Updated: 2022-03-04

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

RecruitingNCT05855200

GlaxoSmithKlineColonic Neoplasms, Neoplasms, Colon

Start: 2023-08-01End: 2031-03-27Target: 892Updated: 2026-01-23

Unknown Phase

Apatinib for Resectable Colorectal Cancer

WithdrawnNCT03228043

Nanchong Central HospitalAdjuvant Chemotherapy, Apatinib, Colorectal Cancer +2

Start: 2020-03-01End: 2023-03-01Updated: 2024-11-14

Journal of Clinical Oncology2026-01-10

Phase II trial of adjuvant toripalimab in stage IIb, IIc, or III colon cancer with mismatch repair deficiency.

Journal of Clinical Oncology2026-01-10

A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.

2026-01-06

AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer.

Journal of Clinical Oncology2025-05-28

Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial

Clinical Cancer Research2024-11-045 citations

First-line regorafenib with nivolumab and FOLFOX or CapeOX in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: A single-arm, phase Ib/II trial (REGONIVOCTx, EPOC2104).

Journal of Clinical Oncology2024-06-01

AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer.

Journal of Clinical Oncology2024-01-205 citations